No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Specialties
Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of in vitro diagnostic reagents and medical testing equipment and services in China and internationally. The company offers immunoassay and clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management solution, and automated comprehensive solutions for nucleic acid blood screening. It also provides automatic modular and clinical chemistry analyzers and clinical chemistry reagents test menu; automatic chemiluminescence immunoassay analyzers and CLIA reagents test menu; automatic ELISA microplate readers, ELISA microplate washers, and enzyme-linked immunoassay reagents; and diagnostics kit for HIV and SARS-CoV-2 IgM/IgG antibody, HIV I/II Ab rapid tests, diagnostic kit for Hepatitis B surface antigen and Hepatitis C virus antibody, and diagnostic kit for antibody to T. Palladium. In addition, the company offers molecular diagnostics solutions, including fully automated nucleic acid blood screening laboratory solution and nucleic acid testing and detection kits; automatic multifunctional veterinary analyzer; and mass spectrometry. It exports its products. The company serves healthcare institutions, blood centers, disease control and prevention centers, and research organizations. Its products are used in clinical diagnostics, blood screening, public health, food safety, and scientific research applications. The company was founded in 1981 and is headquartered in Shanghai, China.
www.skhb.comNo one on the platform currently holds 002022.SZ.
No tracked institution reports a position in 002022.SZ as of their last filing.
No one on the platform has traded 002022.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -6.6% | -16.9% | ||||
| Profit Margin % | -44.6% | -11.8% | 0.6% | |||
| Free Cash Flow Margin % | -7.1% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.6B | — | $0.46 | $0.46–$0.46 | — | 1 |
| 2027 | $2.0B | +30.6% | $0.46 | $0.46–$0.46 | — | 1 |
| 2028 | $2.3B | +11.4% | $0.42 | $0.42–$0.42 | — | 1 |
| 2029 | $3.2B | +40.9% | $0.62 | $0.62–$0.62 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 0 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-21 | $0.09 | $-0.11 | -216.2% |
| 2026-04-27 | $0.09 | $-0.09 | -199.5% |
| 2026-04-16 | $0.13 | $-0.97 | -868.0% |
| 2025-10-29 | $0.13 | $-0.19 | -250.4% |
| 2025-08-26 | $0.13 | $-0.16 | -226.7% |
| 2025-04-29 | $0.09 | $-0.10 | -205.6% |
| 2025-04-27 | $0.09 | $-1.03 | -1240.3% |
| 2024-10-21 | $0.09 |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 002022.SZShanghai Kehua Bio-engineering Co., Ltd. | $5.50 | -0.90% | $2.8B | — |
| 300246.SZGuangdong Biolight Meditech Co., Ltd. | $14.48 | -1.16% | $3.8B | — |
| 300289.SZBeijing Leadman Biochemistry Co.,Ltd. | $5.61 | -0.71% | $3.1B | — |
| 300562.SZGuangdong Transtek Medical Electronics Co., Ltd | $16.52 | -1.31% | $3.6B | — |
| 300642.SZTellgen Corporation |
| $-0.14 |
| -255.0% |
| $16.12 |
| -0.80% |
| $2.6B |
| — |
| 603387.SSGetein Biotech, Inc | $9.06 | -0.22% | $4.6B | — |
| 605186.SSShanghai General Healthy Information and Technology Co., Ltd. | $24.75 | -0.72% | $3.4B | — |
Source: Financial Modeling Prep · peers by sector/industry